1Geisler CH,Kolstad A,Laurell A,et al.Long-term progression-free survival of mantle cell lymphoma following intensive front-line im-munochemotherapy with in vivo-purged stemcell rescue:Anon-ran-domized phase-IImulticenterstudybythe Nordic Lymphoma Group[].Blood.2008
2Maloney DG.Treatment of follicular non-Hodgkin’s lymphoma[].Current Hematology Reports.2005
3ForstpointnerR,UnterhaltM,DreylingM,etal.Maintenance therapy with rituximab leads to a significant prolongation of response dura-tion after salvage therapy with a combination of rituximab,fludara-bine,cyclophosphamide,and mitoxantrone(R-FCM)in patients with recurring and refractory follicular an[].Blood.2006
4Hochster HS,Weller E,Gascoyne RD,et al.Maintenance rituximab after CVPresults in superiorclinical outcome in advanced follicular lymphoma(FL):results of the E1496phase III trial fromthe East-ern Cooperative Oncology Group and the Cancer and Leukemia Group B[abstract][].Blood.2005
5Pfreundschuh M,Schubert J,Ziepert M,et al.Six versus eight cy-cles of bi-weeklyCHOP-14with orwithoutrituximab in elderlypa-tients with diffuse large B-cell lymphomas:a randomised controlled trial(RICOVER-60)[].The Lancet Oncology.2008
6Beum PV,Kennedy AD,Williams ME,et al.The shaving reaction:rituximab/CD20complexes are removed frommantle cell lymphoma and chronic lymphocytic leukemia cells byTHP-1monocytes[].J Im-munol.2006
7Pfreundschuch M,Kloess M,Schmits R,et al.Six,not eight cycles of Bi-weekly CHOP with rituximab(R-CHOP-14)is the preferred treatment for elderly patients with diffuse large B-cell lymphoma(DLBCL):results of the RICOVER-60trial of the German High-grade Non-Hodgkin Lymphoma Study Group(DSHNHL)[ab-s[].Blood.2005
8Cragg,MS,Walshe,CA,Ivanov,AO,Glennie,MJ.The biology of CD20 and its potential as a target for mAb therapy[].Current Directions in Autoimmunity.2005
9Niwa,R,Hatanaka,S,Shoji-Hosaka,E,Sakurada,M,Kobayashi,Y,Uehara,A,Yokoi,H,Nakamura,K,Shitara,K.Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgRIIIa functional polymorphism[].Clinical Cancer Research.2004
10van Meerten, T,van Rijn, R.S,Hoi, S,Hagenbeek, A,& Ebeling, S.B.Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity[].Clinical Cancer Research.2006
7Dworzak M N,Schumich A,Printz D,et al.CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment:setting the stage for anti-CD20 directed immunotherapy[J].Blood,2008,112(10):3982-3988.
8Zhou X,Hu W,Qin X.The role of complement in the mechanism of action of rituximab for B-cell lymphoma:implications for therapy[J].Oncologist,2008,13(9):954-966.
9van Meerten T,Hagenbeek A.CD20-targeted therapy:a breakthrough in the treatment of non-Hodgkin's lymphoma[J].Neth J Med,2009,67(7):251-259.
10Sieber S,Gdynia G,Roth W,et al.Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate[J].Int J Oncol,2009,35(1):149-158.
